Has this billion-dollar fund made the right call on ARRY, VRX, and HIMX?
Three key biopharma trades from the highly-successful $78 billion Renaissance fund
Ortho Dermatologics, a division of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced it has submitted a New Drug Application (NDA) to the FDA for IDP-118 (halobetasol propionate …
Irina Rivkind Koffler Doubles Down on Bearish Bet
Greenblatt’s Gotham Management Turns Bullish on These 3 Biotech Stocks
Two Pharmaceutical Companies that Have Recently Found Themselves in Hot Water Look for Relief
H.C.
Analyst Gregg Gilbert of Deutsche Bank remains on the fence with Valeant Pharmaceuticals Intl Inc (NYSE:VRX) after mixed second-quarter results. The company’s EPS …
Valeant’s Good News- Manufacturing Qualms Could Be Put at Rest Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has revealed the FDA’s confirmed intention to issue …
Trading pioneer Cliff Asness displayed a bearish attitude to a number of key stocks in the last quarter, including Valeant Pharmaceuticals Intl …